Collegium Announces $50 Million Accelerated Share Repurchase Program
Rhea-AI Summary
Collegium (Nasdaq: COLL) entered a $50 million Accelerated Share Repurchase (ASR) agreement with Jefferies to buy back its common stock, under the $150 million repurchase program authorized in July 2025. After this ASR, $100 million will remain available under the broader program.
Collegium will pay $50 million and receive an initial 1,556,420 shares, calculated using the $25.70 closing price on August 12, 2026, representing about 80% of the total shares expected under the ASR. The final number of shares will be based on volume-weighted average prices during the ASR term, with settlement expected by the fourth quarter of 2026. As of June 30, 2026, Collegium reported 32.5 million shares outstanding.
Positive
- $50 million ASR advances execution of the $150 million repurchase program
- Initial 1,556,420 shares delivered upfront based on $25.70 August 12, 2026 close
- $100 million repurchase capacity remains under the July 2025 authorization
- ASR structure provides near-term share delivery with pricing based on future VWAP
Negative
- $50 million cash outlay committed to repurchases, reducing funds available for other uses
- Final share count depends on future volume-weighted average prices, introducing pricing uncertainty
News Explained
The
Key Figures
Previous Buybacks Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | share repurchase program | Positive | +1.8% | New authorization replaced a prior program with unused capacity. |
| May 12 | accelerated share repurchase | Positive | +2.3% | Jefferies ASR included an initial delivery of repurchased shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Buyback-tagged announcements were followed by positive 24-hour reactions in both available events.
Key Terms
volume-weighted average prices financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase
“Collegium’s strong financial position, rapidly growing ADHD portfolio and robust cash generation provide us with substantial flexibility to execute our disciplined capital allocation strategy," said Vikram Karnani, President and Chief Executive Officer. "Given our confidence in the long-term growth trajectory of our ADHD portfolio and the expected durability of our pain business, we believe our current valuation does not fully reflect the strength of our business or our future prospects. Accordingly, we view this share repurchase program as a compelling opportunity to create long-term shareholder value. As we continue to grow, we remain committed to a balanced capital allocation strategy that includes investing behind our key growth drivers, further diversifying our portfolio, rapidly reducing debt and opportunistically repurchasing shares."
Under terms of the agreement, Collegium will pay
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to the share repurchase program, the transactions under the ASR and the expected completion date of the ASR, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: developments or changes in the securities markets and fluctuations in the trading volume and market price of the Company's common stock; unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com
